Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026
Company Deals

Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia

Fineline Cube Apr 7, 2023

China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn...

Company Deals

Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241

Fineline Cube Apr 7, 2023

US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...

Company Deals

Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China

Fineline Cube Apr 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district...

Company Drug

Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study

Fineline Cube Apr 6, 2023

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...

Company Drug

Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment

Fineline Cube Apr 6, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...

Company Drug

Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data

Fineline Cube Apr 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its...

Company Deals R&D

Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development

Fineline Cube Apr 6, 2023

The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of...

Company Drug

AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital

Fineline Cube Apr 6, 2023

AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...

Policy / Regulatory

Provincial Budgets Highlight Top Earning Hospitals in China for 2023

Fineline Cube Apr 6, 2023

Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a...

Company Drug

Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan

Fineline Cube Apr 6, 2023

Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...

Company Deals

Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector

Fineline Cube Apr 6, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company

AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role

Fineline Cube Apr 6, 2023

Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV),...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials

Fineline Cube Apr 6, 2023

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for Review by Singapore’s HSA

Fineline Cube Apr 6, 2023

China-based Everest Medicines (HKG: 1952) has announced that the Health Sciences Authority (HSA) of Singapore...

Company Drug

Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys

Fineline Cube Apr 6, 2023

China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...

Company Deals

Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda

Fineline Cube Apr 6, 2023

China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme...

Company Deals R&D

AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups

Fineline Cube Apr 6, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....

Company Drug

CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer

Fineline Cube Apr 6, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B

Fineline Cube Apr 6, 2023

Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...

Company Deals

Shanghai Best-Link Bioscience Secures $29 Million in Series A Financing for Nano Drug Innovation

Fineline Cube Apr 6, 2023

Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai,...

Posts pagination

1 … 523 524 525 … 648

Recent updates

  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
  • Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.